Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00883896

Public ClinicalTrials.gov record NCT00883896. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY TO SUBJECT WITH RHEUMATOID ARTHRITIS.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate.

Study identification

NCT ID
NCT00883896
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
195 participants

Conditions and interventions

Interventions

Other · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 17, 2009
Primary completion
Feb 17, 2011
Completion
Feb 17, 2011
Last update posted
Oct 20, 2022

2009 – 2011

United States locations

U.S. sites
13
U.S. states
8
U.S. cities
12
Facility City State ZIP Site status
Arizona Arthritis & Rheumatology Research, PLLC Glendale Arizona 85304
Desert Medical Advances Palm Desert California 92260
Arthritis Center Palm Harbor Florida 34684
Clinical Research Advantage, Inc. Sarasota Florida 34233
The Arthritis Specialty Centre Sarasota Florida 34233
Diagnostic Rheumatology and Research PC Indianapolis Indiana 46227
Clayton Medical Research St Louis Missouri 63117
Deaconess Hospital Cincinnati Ohio 45219
Altoona Center for Clinical Research Duncansville Pennsylvania 16635
Clinical Research Center of Reading West Reading Pennsylvania 19611
Clinical Research Center of Reading, LLC Wyomissing Pennsylvania 19610
Arthritis Care and Diagnostic Center Dallas Texas 75231
Arthritis & Osteoporosis Center of South Texas San Antonio Texas 78232

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00883896, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2022 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00883896 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →